Transcriptional Activity of Human Epidermal Growth Factor Receptor Family and Angiogenesis Effectors in Locoregionally Recurrent Head and Neck Squamous Cell Carcinoma and Correlation with Patient Outcome

Table 1

Clinicopathological characteristics at initial diagnosis and locoregional relapse.

	𝑁=41
	At diagnosis		At recurrence
Age
Median (range)	65 (45–77)
Relapse-free interval (months)
Median (range)			15 (5–221)
Size (cm)
Median (range)	2 (0.3–6)		2.6 (0.6–10)
	𝑁	%	𝑁	%
Gender
Male	41	100
Family history
No	29	71
Yes	12	29
Smoking history
No	2	5	28	68
Yes	39	95	13	32
Pack years
Median (range)	52.5 (0–125)
Alcohol consumption
Low	13	32
Moderate	16	39
High	12	29
Symptoms
Hoarseness	26	63
Dyshphagia	10	24
Dyspnoea	1	2
Sore mouth	2	5
Ulceration	1	2
Lymphadenopathy	1	2
Primary site
Glottic	26	63
Supraglottic	10	24
Transglottic	1	2
Oropharynx	3	7
Unknown primary	1	2
Site of recurrence
Local			27	66
Lymph nodes ± local			6	15
Other			8	19
T stage
T1	16	39
T2	12	29
T3	8	20
T4	4	10
Unknown	1	2
N stage
N0	35	85
N1	3	7
N2	1	2
Unknown	2	5
Grade
I	7	17	9	22
II	18	44	16	39
III	5	12	7	17
IV	1	2	2	5
In Situ	1	2	0	0
Verrucous	1	2	1	2
Unknown	8	20	6	15
Surgery
Biopsy	13	32	14	34
Total laryngectomy ± nodal resection	10	24	19	46
Hemilaryngectomy or segmental resection	8	19	1	2
Local resection	10	24	7	17
Radiotherapy (RT)
No	20	49	30	73
Yes	21	51	10	24
Unknown	0	0	1	2
RT dose (Gy)
Median (range)	66 (64–74)		69 (40–72)
Chemotherapy (CT)
No	40	98	30	73
Yes	1	2	10	24
Unknown	0	0	1	2
CT duration (months)
Median (range)			3.7 (1.8–5.0)
Radiotherapy only	20	49	7	17
Chemotherapy only	0	0	7	17
Paclitaxel + gemcitabine			1
Paclitaxel + liposomal doxorubicin			3
Methotrexate			1
Missing data			2
Surgery only	19	46	19	46
Chemoradiotherapy	1	2	3	7
Paclitaxel + gemcitabine			1
Paclitaxel + liposomal doxorubicin			1
Missing data			1